Table 1

Hemodynamic response to coronary artery occlusion before and after KATP antagonists

PreocclusionOcclusion
HR (beats/min)
 No drug188.7  ± 16.3220.0  ± 14.71-b
 HMR 1883182.6  ± 17.8216.0  ± 13.91-b
 Glibenclamide187.4  ± 11.7202.8  ± 9.21-b
LVSP (mm Hg)
 No drug154.9  ± 6.7133.6  ± 8.81-b
 HMR 1883148.7  ± 8.0135.9  ± 12.91-b
 Glibenclamide146.2  ± 7.8123.1  ± 8.91-b
Left ventricular dP/dt maximum (mm Hg/sec)
 No drug5278  ± 372.44479  ± 361.71-b
 HMR 18834876  ± 345.84423  ± 192.11-b
 Glibenclamide3571  ± 399.81-a 3099  ± 508.7

  • ↵1-a P < .01, No drug vs. drug treatment.

  • ↵1-b P < .01, Preocclusion vs. occlusion.

  • Glibenclamide = 1.0 mg/kg i.v., HMR 1883 = 3.0 mg/kg i.v.